Distinct Side Population Cell Subtypes Have Different Stemness Levels in Human Ovarian Cancer Cells

Curr Med Sci. 2021 Feb;41(1):127-132. doi: 10.1007/s11596-021-2327-0. Epub 2021 Feb 13.

Abstract

The stemness of different side population (SP) cell subtypes in ovarian cancer cells was studied, and the heterogeneity of ovarian cancer stem cells was analyzed. The cisplatin-resistant human serous ovarian cancer cell line C13 was stained with the bisbenzimide Hoechst 33342. A flow cytometry-based fluorescence-activated sorting method was used to obtain lower-SP (LSP) cells, upper-SP (USP) cells, and non-SP cells (NSP) based on their sensitivity to the staining time and Hoechst dye concentration. The sphere-forming capability, expression levels of stem cell markers, resistance to high concentrations of cisplatin, and subcutaneous tumorigenicity in NOD/SCID mice of the different cell subtypes were evaluated. The C13 cells contained SP cells with stemness characteristics, and the LSP cell subtype expressed higher levels of stem cell markers, had higher in vitro sphere-forming capability, higher cisplatin resistance and higher in vivo subcutaneous tumorigenesis than USP cells (P<0.05). NSP cells had no stemness. In conclusion, different subtypes of ovarian cancer SP cells have different stemness levels, and ovarian cancer stem cells may be heterogeneous.

Keywords: cancer stem cells; heterogeneity; ovarian cancer; side population.

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Carcinogenesis / pathology
  • Cell Line, Tumor
  • Cell Self Renewal*
  • Cisplatin / pharmacology
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Neoplastic Stem Cells / classification*
  • Neoplastic Stem Cells / drug effects
  • Neoplastic Stem Cells / physiology
  • Ovarian Neoplasms / pathology*
  • Tumor Stem Cell Assay

Substances

  • Antineoplastic Agents
  • Cisplatin